Mohamed A Hammoud1, Stefanie Vaccher2, Fengyi Jin3, Adam Bourne4, Bridget Haire5, Lisa Maher6, Toby Lea7, Garrett Prestage8. 1. The Kirby Institute, UNSW, Sydney, Australia. Electronic address: mhammoud@kirby.unsw.edu.au. 2. The Kirby Institute, UNSW, Sydney, Australia. Electronic address: svaccher@kirby.unsw.edu.au. 3. The Kirby Institute, UNSW, Sydney, Australia. Electronic address: jjin@kirby.unsw.edu.au. 4. Australian Research Centre in Sex Health and Society, La Trobe University, Australia. Electronic address: a.bourne@latrobe.edu.au. 5. The Kirby Institute, UNSW, Sydney, Australia. Electronic address: b.haire@unsw.edu.au. 6. The Kirby Institute, UNSW, Sydney, Australia. Electronic address: lmaher@kirby.unsw.edu.au. 7. Centre for Social Research in Health, UNSW, Sydney, Australia. Electronic address: toby.lea@unsw.edu.au. 8. The Kirby Institute, UNSW, Sydney, Australia. Electronic address: gprestage@kirby.unsw.edu.au.
Abstract
INTRODUCTION: Gay and bisexual men (GBM) often use illicit drugs to enhance sexual pleasure, commonly referred to as 'chemsex' or 'party n play'. In particular, the use of methamphetamine and Viagra™, and other erectile dysfunction medications, both together and separately are strongly predictive of subsequent HIV infection. Truvada™, as pre-exposure prophylaxis (PrEP), virtually eliminates HIV transmission during condomless anal intercourse (CLAI). HIV-negative GBM in intensive sex partying networks may be adding PrEP to their drug regimen to actively reduce the possibility of HIV transmission during chemsex. AIM: We describe the prevalence and context of concurrent use of methamphetamine, Truvada™ (or its generic formulations), and Viagra™ or other erectile dysfunction medication (collectively, MTV). METHOD: The Following Lives Undergoing Change study is an online prospective observational study of licit and illicit drug use among Australian GBM. Between January and July 2017, 1831 GBM provided details about their use of MTV. Binary logistic multiple regression analysis were used to estimate adjusted odds ratios (aOR) and associated 95% confidence intervals (95%CI). RESULTS: Concurrent MTV use was reported by 6.0% of participants; 3.1% used methamphetamine and Viagra™ or other erectile dysfunction medication ('MV only') and 11.2% used Truvada™ as PrEP ('T only'). In multivariate analysis, compared to use of 'MV only', MTV was independently associated with CLAI with casual partners (aOR = 6.78;95%CI = 1.42-32.34) and 'fuckbuddies' (aOR = 3.47;95%CI = 1.41-8.56) in the previous six months. Compared to use of 'T only', MTV was independently associated with being older (aOR = 3.95;95%CI = 1.55-10.03) and engaging in group sex (aOR = 3.31;95%CI = 1.82-6.00). Greater social engagement with other gay men (aOR = 1.44;95%CI = 1.18-1.76) and having more sexual partners (aOR = 2.30;95%CI = 1.10-4.82) were independently associated with use of MTV compared to use of 'MV only' or 'T only'. CONCLUSION: GBM in intensive sex partying networks are increasingly adding PrEP alongside other drugs they use to enhance sexual experiences. Interventions that promote the use of PrEP during chemsex could mitigate HIV risk.
INTRODUCTION: Gay and bisexual men (GBM) often use illicit drugs to enhance sexual pleasure, commonly referred to as 'chemsex' or 'party n play'. In particular, the use of methamphetamine and Viagra™, and other erectile dysfunction medications, both together and separately are strongly predictive of subsequent HIV infection. Truvada™, as pre-exposure prophylaxis (PrEP), virtually eliminates HIV transmission during condomless anal intercourse (CLAI). HIV-negative GBM in intensive sex partying networks may be adding PrEP to their drug regimen to actively reduce the possibility of HIV transmission during chemsex. AIM: We describe the prevalence and context of concurrent use of methamphetamine, Truvada™ (or its generic formulations), and Viagra™ or other erectile dysfunction medication (collectively, MTV). METHOD: The Following Lives Undergoing Change study is an online prospective observational study of licit and illicit drug use among Australian GBM. Between January and July 2017, 1831 GBM provided details about their use of MTV. Binary logistic multiple regression analysis were used to estimate adjusted odds ratios (aOR) and associated 95% confidence intervals (95%CI). RESULTS: Concurrent MTV use was reported by 6.0% of participants; 3.1% used methamphetamine and Viagra™ or other erectile dysfunction medication ('MV only') and 11.2% used Truvada™ as PrEP ('T only'). In multivariate analysis, compared to use of 'MV only', MTV was independently associated with CLAI with casual partners (aOR = 6.78;95%CI = 1.42-32.34) and 'fuckbuddies' (aOR = 3.47;95%CI = 1.41-8.56) in the previous six months. Compared to use of 'T only', MTV was independently associated with being older (aOR = 3.95;95%CI = 1.55-10.03) and engaging in group sex (aOR = 3.31;95%CI = 1.82-6.00). Greater social engagement with other gay men (aOR = 1.44;95%CI = 1.18-1.76) and having more sexual partners (aOR = 2.30;95%CI = 1.10-4.82) were independently associated with use of MTV compared to use of 'MV only' or 'T only'. CONCLUSION: GBM in intensive sex partying networks are increasingly adding PrEP alongside other drugs they use to enhance sexual experiences. Interventions that promote the use of PrEP during chemsex could mitigate HIV risk.
Authors: Denton Callander; Su Hyun Park; Yazan A Al-Ajlouni; John A Schneider; Maria R Khan; Steven A Safren; Dustin T Duncan Journal: AIDS Educ Prev Date: 2019-04
Authors: Mariano Kanamori; Cho-Hee Shrader; Ariana Johnson; Juan Arroyo-Flores; Edda Rodriguez; John Skvoretz; Stephen Fallon; Victor Gonzalez; Steven Safren; Mark Williams; Susanne Doblecki-Lewis Journal: Arch Sex Behav Date: 2021-11-17
Authors: Sophia A Hussen; Daniel M Camp; Marxavian D Jones; Shivani A Patel; Natalie D Crawford; David P Holland; Hannah L F Cooper Journal: Int J Drug Policy Date: 2021-01-09
Authors: Johann Kolstee; Martin Holt; Jeff Jin; Mohamed A Hammoud; Louisa Degenhardt; Lisa Maher; Toby Lea; Garrett Prestage Journal: PLoS One Date: 2020-06-01 Impact factor: 3.240
Authors: Ymke J Evers; Geneviève A F S Van Liere; Christian J P A Hoebe; Nicole H T M Dukers-Muijrers Journal: PLoS One Date: 2019-05-14 Impact factor: 3.240
Authors: Mitzy Gafos; Rob Horne; Will Nutland; Gill Bell; Caroline Rae; Sonali Wayal; Michael Rayment; Amanda Clarke; Gabriel Schembri; Richard Gilson; Alan McOwan; Ann Sullivan; Julie Fox; Vanessa Apea; Claire Dewsnap; David Dolling; Ellen White; Elizabeth Brodnicki; Gemma Wood; David Dunn; Sheena McCormack Journal: AIDS Behav Date: 2019-07